COMPASS Pathways

CMPS Lead: NDA Submitted 8 Biotech Distilled articles ↓

Most recent annual filing: 2025-02-15

Catalyst timeline

COMP360 TRD NDA filing4Q 2026COMP360 TRD NDA filing, 4Q 2026, notable

Bar width shows how precise the guidance is — a pin is a stated date, a wide band a six-month window. Deeper blue means more of the thesis rides on the event; it is not a view on the stock.

Pipeline (3 active programs)

psilocybin

COMP360

Small Molecule Target: 5-HT2A receptor

Treatment-Resistant Depression NDA Submitted NCT03775200
Post-Traumatic Stress Disorder Phase 2 Phase 2b/3 trial NCT05312151
Anorexia Nervosa Phase 2 NCT04661514

Biotech Distilled coverage (8)

2026-08-07 UPDATE: Compass Pathways (CMPS) - The VA Just Became a Customer Before It’s a Customer 🔒 Paid
2026-08-06 UPDATE: Compass Pathways (CMPS) - The $253 Million Loss That Isn’t 🔒 Paid
2026-07-07 UPDATE: Compass Pathways (CMPS) - The Last Piece of Clinical Risk Just Got Retired 🔒 Paid
2026-04-27 UPDATE: Compass Pathways (CMPS) - The Regulatory Anvil Just Got Lifted 🔒 Paid
2026-03-28 UPDATE: Compass Pathways (CMPS) - The Accounting Trap Net Loss and the 7,300-Center Flex 🔒 Paid
2026-02-28 UPDATE: Compass Pathways (CMPS) – The $341 Million Dilution Double-Tap 🔒 Paid
2026-02-21 UPDATE: Compass Pathways (CMPS) – The Coin Lands Heads, and the Bill Comes Due 🔒 Paid
2026-01-15 Compass Pathways (CMPS): Scientific Deep Dive for COMP360 and Pipeline Products 🔒 Paid

Articles open on Substack. Some deep dives are subscriber-only.